Nebenwirkungen · MenQuadfi
MenQuadfi solution for injection Meningococcal Group A, C, W and Y conjugate vaccine MenACWY · Abschnitt 4.8 · PDF-Seite 7
HOS-144207 · Präparat HOS-099130
• Overall, rates of adverse reactions were higher in toddlers aged 12-23 months of age who received PCV13 given concomitantly with MenQuadfi (36.5%) than in toddlers who received PCV13 alone (17.2%). • Rates of injection site pain at the 9vHPV injection site were higher when children and adolescents aged 10-17 years of age were given MenQuadfi concomitantly with the first dose of Tdap-IPV (83.6%) compared to when Tdap-IPV and 9vHPV were given without MenQuadfi (67.3%). • Higher rates and intensity of solicited adverse reactions were observed in participants aged 12 to 13 months and 13 to 26 years of age. Higher rates of unsolicited adverse reactions were observed in participants aged 12 to 13 months, who received MenQuadfi concomitantly with a meningococcal serogroup B vaccine (MenB), compared to when MenQuadfi was administered alone.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-18T10:00:00Z · SHA-256 ebec4745bfdc370a0e03b2fca938d4349a0aa60a9b6f828972f5fba03ef36517 · Passage 312809ec26a411a8e80f2e533f7f709ecb0920fd8e87f8a59ed4323d67ce7676 · Zeichen 1760–2674 im Abschnitt